For research use only. Not for therapeutic Use.
Ganciclovir (INN) is an antiviral medication used to treat or prevent cytomegalovirus (CMV) infections. Ganciclovir is a synthetic analogue of 2′-deoxy-guanosine. It is first phosphorylated to ganciclovir monophosphate by a viral kinase encoded by the cytomegalovirus (CMV) gene UL97 during infection. Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in CMV or herpes simplex virus (HSV)-infected cells than uninfected cells. A prodrug form with improved oral bioavailability (valganciclovir) has also been developed.
| Catalog Number | A001164 |
| CAS Number | 82410-32-0 |
| Synonyms | RS-21592, BW-759 |
| Molecular Formula | C₉H₁₃N₅O₄ |
| Purity | ≥95% |
| Target | HSV |
| Solubility | Soluble in DMSO > 10 mM |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) |
| InChIKey | IRSCQMHQWWYFCW-UHFFFAOYSA-N |
| SMILES | C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N |
| Reference | </br>1:A common anti-CMV drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo. Vanpouille C, Bernatchez JA, Lisco A, Arakelyan A, Saba E, Götte M, Margolis L.AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001532. [Epub ahead of print] PMID: 28481774 </br>2:Differentiated levels of ganciclovir resistance conferred by mutations at codons 591-603 of the cytomegalovirus UL97 kinase gene. Chou S, Ercolani RJ, Vanarsdall AL.J Clin Microbiol. 2017 Apr 26. pii: JCM.00391-17. doi: 10.1128/JCM.00391-17. [Epub ahead of print] PMID: 28446569 </br>3:Topical Ganciclovir in Cytomegalovirus Anterior Uveitis. Antoun J, Willermain F, Makhoul D, Motulsky E, Caspers L, Relvas LJ.J Ocul Pharmacol Ther. 2017 May;33(4):313-318. doi: 10.1089/jop.2016.0138. Epub 2017 Apr 20. PMID: 28426277 </br>4:Risk Factors and Outcomes of Ganciclovir Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients. Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M, Limaye AP.Clin Infect Dis. 2017 Mar 29. doi: 10.1093/cid/cix259. [Epub ahead of print] PMID: 28369203 </br>5:Combined environmental risk assessment for the antiviral pharmaceuticals ganciclovir and valganciclovir in Europe. Straub JO.Environ Toxicol Chem. 2017 Feb 15. doi: 10.1002/etc.3758. [Epub ahead of print] PMID: 28198039 </br>6:[Intravitreal ganciclovir as an additional therapy option in acute retinal necrosis]. Bischoff-Jung M, Viestenz A, Fiorentzis M, Daas L, Seitz B, Pappas G, Viestenz A.Ophthalmologe. 2017 Jan 19. doi: 10.1007/s00347-016-0398-2. [Epub ahead of print] German. PMID: 28105484 </br>7:Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review. Bright PD, Gompels M, Donati M, Johnston S.J Clin Virol. 2017 Feb;87:12-16. doi: 10.1016/j.jcv.2016.12.006. Epub 2016 Dec 12. No abstract available. PMID: 27987421 </br>8:Ganciclovir-induced ataxia and encephalopathy. Möhlmann MC, Stiksma J, Kramer MH.Neth J Med. 2016 Dec;74(10):449-450. PMID: 27966439 Free Article</br>9:Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients. Bonatti H, Sifri CD, Larcher C, Schneeberger S, Kotton C, Geltner C.Surg Infect (Larchmt). 2017 Feb/Mar;18(2):128-136. doi: 10.1089/sur.2015.266. Epub 2016 Nov 16. PMID: 27849440 </br>10:Studies on the interference of ganciclovir to HCV liver fibrosis. Li J, Pan CW, Zhou GY, Zhuge L, Fang PP, Jin LX, Lin W, Lin XZ, Zheng Y.Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4343-4347. PMID: 27831637 Free Article |
